Courtney Flaherty

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Four experts share their perspectives on the potential challenges and future directions for AI integration in the field of oncology.

ETX-636, a selective PI3Kα inhibitor, has received FDA fast track designation for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer.

Crofelemer may receive ODD for diarrhea treatment in patients with breast cancer and brain metastases receiving targeted therapy with/without chemotherapy.

Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.

Giredestrant plus everolimus improved PFS vs SOC endocrine therapy plus everolimus in CDK4/6 inhibitor–pretreated, ER-positive breast cancer.

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

The EMA’s CHMP has recommended the approval of subcutaneous pembrolizumab across all indications and perioperative pembrolizumab in locally advanced HNSCC.

David Miklos, MD, PhD, discusses the potential role for Orca-T vs standard PTCy after allogeneic transplant in hematologic malignancies.

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.

The FDA has provided guidance on the design of a potential phase 3 trial evaluating the ADC ozuriftamab vedotin in OPSCC.

A correlation between ctDNA negativity in the post-surgical MRD window and improved RFS and OS was observed with the Signatera Genome assay in NSCLC.

Topline results from the BRUIN CLL-313 study show a significant improvement in PFS with pirtobrutinib vs chemoimmunotherapy in treatment-naive CLL/SLL.

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

The FDA has granted breakthrough therapy designation to zongertinib in the first line for nonsquamous NSCLC harboring HER2 TKD activating mutations.

Christopher Phillips, PharmD, discusses the advantages of liquid drug formulations over tablets and capsules for select pediatric or adult patients with cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

Andrea Necchi, MD, discusses how initial findings from the SURE-02 study indicate the potential for bladder preservation over cystectomy in MIBC.

In an OncLive® Peer Exchange, 4 panelists discuss navigating fixed-duration vs continuous therapy in CLL.

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

Following cuts to federal funding for health agencies, concerns about the long-term consequences for research programs in the US are escalating.

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.